# Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO

> **NCT01624571** · PHASE2 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 147 (actual)

## Conditions studied

- Colon Resection
- _large Interstinal Surgery

## Interventions

- **DRUG:** LD02GIFRO

## Key facts

- **NCT ID:** NCT01624571
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2013-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624571, "Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01624571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*